Letter to the editor: Regression of liver fibrosis after bariatric operations: A glass two‐third full rather than half empty
François Pattou, Guillaume Lasailly, Violeta Raverdy, Robert Caiazzo, Philippe Mathurin – 7 April 2022
Neighborhood poverty is associated with failure to be waitlisted and death during liver transplantation evaluation
Kawthar A. Mohamed, Marwan Ghabril, Archita Desai, Eric Orman, Kavish R. Patidar, John Holden, Susan Rawl, Naga Chalasani, Chandra Shekhar Kubal, Lauren Nephew – 6 April 2022 – Liver transplantation (LT) is the final step in a complex care cascade. Little is known about how race, gender, rural versus urban residence, or neighborhood socioeconomic indicators impact a patient's likelihood of LT waitlisting or risk of death during LT evaluation. We performed a retrospective cohort study of adults referred for LT to the Indiana University Academic Medical Center from 2011 to 2018.
Severe acute respiratory syndrome coronavirus 2 antibody response to a third dose of homologous messenger RNA vaccination in liver transplantation recipients
Alexandra T. Strauss, Amy Chang, Jennifer L. Alejo, Teresa P.‐Y. Chiang, Nicole F. Hernandez, Laura B. Zeiser, Brian J. Boyarsky, Robin K. Avery, Aaron A. R. Tobian, Macey L. Levan, Daniel S. Warren, Allan B. Massie, Jacqueline M. Garonzik‐Wang, Dorry L. Segev, William A. Werbel – 6 April 2022
C‐X‐C motif chemokine ligand 1 induced by Hedgehog signaling promotes mouse extrahepatic bile duct repair after acute injury
Nureen H. Mohamad Zaki, Junya Shiota, Ashley N. Calder, Theresa M. Keeley, Benjamin L. Allen, Kazuhiko Nakao, Linda C. Samuelson, Nataliya Razumilava – 6 April 2022
Occludin stalls HCV particle dynamics apart from hepatocyte tight junctions, promoting virion internalization
Maika S. Deffieu, Camille M. H Clément, Cristina M. Dorobantu, Emma Partiot, Yonis Bare, Orestis Faklaris, Benjamin Rivière, Nilda Vanesa Ayala‐Nunez, Thomas F. Baumert, Philippe Rondé, Yves Mély, Vincent Lucansky, Raphael Gaudin – 6 April 2022
Retuning hepatocytes improves their functional engraftment
Jan S. Tchorz – 6 April 2022
Changing epidemiology of hepatocellular cancer in the United States: Winning the battle but it is not over yet
Saira Khaderi, Fasiha Kanwal – 6 April 2022
New kid on the block: Netrin‐1 as a novel player in the delicate molecular network of hepatic inflammation
Benjamin Goeppert, Stephanie Roessler – 5 April 2022
Fecal microbiota transplant improves cognition in hepatic encephalopathy and its effect varies by donor and recipient
Patricia P. Bloom, John Donlan, Mariam Torres Soto, Michael Daidone, Elizabeth Hohmann, Raymond T. Chung – 4 April 2022 – Early data suggest fecal microbiota transplant (FMT) may treat hepatic encephalopathy (HE). Optimal FMT donor and recipient characteristics are unknown. We assessed the safety and efficacy of FMT in patients with prior overt HE, comparing five FMT donors. We performed an open‐label study of FMT capsules, administered 5 times over 3 weeks. Primary outcomes were change in psychometric HE score (PHES) and serious adverse events (SAEs).